ReP USP - Resultado da busca

Artigo de periodico
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study (2020)
Strom, Peter; Kartasalo, Kimmo; Olsson, Henrik; Solorzano, Leslie; Delahunt, Brett; Berney, Daniel M.; Bostwick, David G; Evans, Andrew J; Grignon, David J; Leite, Katia Ramos Moreira
Source: Lancet oncology. Unidade: FM
Subjects: INTELIGÊNCIA ARTIFICIAL, NEOPLASIAS PROSTÁTICAS, BIÓPSIA POR AGULHA, DESENVOLVIMENTO DE TECNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STROM, Peter et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet oncology, v. 21, n. 2, p. 222-232, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(19)30738-7. Acesso em: 31 out. 2024.
APA
Strom, P., Kartasalo, K., Olsson, H., Solorzano, L., Delahunt, B., Berney, D. M., et al. (2020). Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet oncology, 21( 2), 222-232. doi:10.1016/S1470-2045(19)30738-7
NLM
Strom P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, Leite KRM. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study [Internet]. Lancet oncology. 2020 ; 21( 2): 222-232.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30738-7
Vancouver
Strom P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, Leite KRM. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study [Internet]. Lancet oncology. 2020 ; 21( 2): 222-232.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30738-7
Artigo de periodico
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial (2020)
Coleman, Robert; Finkelstein, Dianne M; Barrios, Carlos; Martin, Miguel; Iwata, Hiroji; Hegg, Roberto; Glaspy, John; Perianez, Alvaro Montano; Tonkin, Katia; Deleu, Ines
Source: Lancet oncology. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, ANTICORPOS MONOCLONAIS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, NEOPLASIAS ÓSSEAS, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COLEMAN, Robert et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, v. 21, n. 1, p. 60-72, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(19)30687-4. Acesso em: 31 out. 2024.
APA
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., et al. (2020). Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, 21( 1), 60-72. doi:10.1016/S1470-2045(19)30687-4
NLM
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Vancouver
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Artigo de periodico
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus (2020)
Mehanna, Hisham; Hardman, John C; Shenson, Jared A; Abou-foul, Ahmad K; Topf, Michael C; Alfalasi, Mohammad; Chan, Jason Y. K; Chaturvedi, Pankaj; Chow, Velda Ling Yu; Kowalski, Luiz Paulo
Source: Lancet oncology. Unidade: FM
Subjects: CABEÇA, ONCOLOGIA, PESCOÇO, RISCO, SERVIÇOS DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEHANNA, Hisham et al. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet oncology, v. 21, n. 7, p. 350-359, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(20)30334-X. Acesso em: 31 out. 2024.
APA
Mehanna, H., Hardman, J. C., Shenson, J. A., Abou-foul, A. K., Topf, M. C., Alfalasi, M., et al. (2020). Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet oncology, 21( 7), 350-359. doi:10.1016/S1470-2045(20)30334-X
NLM
Mehanna H, Hardman JC, Shenson JA, Abou-foul AK, Topf MC, Alfalasi M, Chan JYK, Chaturvedi P, Chow VLY, Kowalski LP. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus [Internet]. Lancet oncology. 2020 ; 21( 7): 350-359.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(20)30334-X
Vancouver
Mehanna H, Hardman JC, Shenson JA, Abou-foul AK, Topf MC, Alfalasi M, Chan JYK, Chaturvedi P, Chow VLY, Kowalski LP. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus [Internet]. Lancet oncology. 2020 ; 21( 7): 350-359.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(20)30334-X
Artigo de periodico
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
Smith, Matthew; Parker, Chris; Saad, Fred; Miller, Kurt; Tombal, Bertrand; Ng, Quan Sing; Boegemann, Martin; Matveev, Vsevolod; Piulats, Josep Maria; Zucca, Luis Eduardo; Nahas, William Carlos
Source: Lancet oncology. Unidade: FM
Subjects: NEOPLASIAS PROSTÁTICAS, METÁSTASE NEOPLÁSICA, NEOPLASIAS ÓSSEAS, ESTEROIDES, ANDRÓGENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SMITH, Matthew et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, v. 20, n. 3, p. 408-419, 2019Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30860-X. Acesso em: 31 out. 2024.
APA
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., et al. (2019). Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20( 3), 408-419. doi:10.1016/S1470-2045(18)30860-X
NLM
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X
Vancouver
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X
Artigo de periodico
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study (2018)
Robak, Tadeusz; Jin, Jie; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Drach, Johannes; Raderer, Markus; Mayer, Jiri; Pereira, Juliana; Tumyan, Gayane
Source: Lancet oncology. Unidade: FM
Subjects: LINFOMA, IMUNOTERAPIA, ESTUDOS RANDOMIZADOS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROBAK, Tadeusz et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, v. 19, n. 11, p. 1449-1458, 2018Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30685-5. Acesso em: 31 out. 2024.
APA
Robak, T., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., et al. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, 19( 11), 1449-1458. doi:10.1016/S1470-2045(18)30685-5
NLM
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5
Vancouver
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies